Quick answer
What is a growth-hormone secretagogue research stack? It is a combination of two compounds that act on the growth-hormone axis through different receptors: a GHRH-receptor ligand such as a modified GRF(1-29) analogue or tesamorelin, and a ghrelin-receptor (GHS-R1a) ligand such as ipamorelin. Research on such pairs asks whether engaging two receptors on the same somatotroph cell gives a different signal from either alone. V8 lists two pre-combined blends in this area, CJC-1295 (no DAC) with ipamorelin and tesamorelin with ipamorelin, plus the individual compounds for investigators who prefer to build their own ratios. A ranking depends on the question, so this guide ranks designs by what they let you test, not by compound.
Lists titled with a superlative invite the wrong question. A stack is not better or worse in the abstract; it is more or less suited to a defined experiment. This guide sets out the receptor logic, the combinations used in the research literature and the V8 catalog, and a way to choose between a pre-mixed blend and separate vials. For laboratory research use only; not for human consumption.
The two receptor routes
Pituitary somatotroph cells carry at least two receptors that govern growth-hormone release. The GHRH receptor responds to growth-hormone-releasing hormone and its analogues. The ghrelin receptor, GHS-R1a, was identified through the discovery of ghrelin by Kojima and colleagues (1999), who showed that a peptide from stomach released growth hormone through a receptor first recognized with synthetic secretagogues. Compounds acting on one receptor or the other are the building blocks of every stack in this area.
| Receptor route | Representative research compounds | V8 page |
|---|---|---|
| GHRH receptor | Sermorelin (GRF 1-29), CJC-1295 (no DAC), tesamorelin | Sermorelin, CJC-1295 no DAC, Tesamorelin |
| Ghrelin receptor (GHS-R1a) | Ipamorelin, GHRP-2, hexarelin | Ipamorelin, GHRP-2, Hexarelin |
Ipamorelin was described by Raun and colleagues (1998) as a growth-hormone secretagogue with selectivity in the models they used. CJC-1295 was characterized by Jetté and colleagues (2005) as a long-lasting GRF analogue in the context of its albumin-conjugated form; the "no DAC" version sold for research is the shorter-acting, unconjugated sequence, a distinction explained in CJC-1295 DAC versus no DAC.
Combinations in the V8 catalog
| Combination | Receptor pairing | Sizes on the product page | Where to read more |
|---|---|---|---|
| CJC-1295 (no DAC) + ipamorelin | GHRH receptor + GHS-R1a | 5 mg / 5 mg and 10 mg / 10 mg | Blend explained |
| Tesamorelin + ipamorelin | GHRH receptor + GHS-R1a | 5 mg / 5 mg and 12 mg / 3 mg | Blend explained |
Both listings give the supplier purity specification of ≥98% and state that the blend is a two-component product whose single-compound pages should be consulted for identity details. The ratios are fixed: for the 12 mg / 3 mg tesamorelin blend, the first number is the mass of the first component and the second the mass of the second, and the formula for the per-component concentration is that component's mass divided by the diluent volume. The calculator on the site does the conversion without any fixed table.
Designs a stack lets you test
- Receptor cooperation. Do the two ligands, applied together to pituitary cell cultures, give a response different from the response predicted from each alone? The answer is framed with a combination-analysis model such as the median-effect method (Chou, 2006) and compared with additivity references (Foucquier and Guedj, 2015).
- Receptor selectivity. With receptor-selective antagonists or single-receptor cell lines, which part of a combined signal belongs to which receptor?
- Pulsatility models. In perifusion systems, does co-application change the pattern of release over time compared with either compound alone?
- Stability in a shared solution. Do both peptides remain intact in one diluent over the planned storage period?
None of these is a statement about outcomes in a living organism. They are bench questions, and each needs single-agent arms, a vehicle control and independent replicates.
Identity data for the building blocks
Because a stack combines molecules with very different sizes, the individual specifications matter when planning molar ratios. The table summarizes what the V8 product pages list.
| Compound | Formula on page | Sequence note on page | Size listed |
|---|---|---|---|
| Ipamorelin | C38H49N9O5 | Aib-His-D-2-Nal-D-Phe-Lys-NH2 (pentapeptide) | 10 mg |
| GHRP-2 | C45H55N9O6 | D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2 | 10 mg |
| Hexarelin | C47H58N12O6 | His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 | 5 mg |
| Sermorelin | C149H246N44O42S | 29-residue GHRH(1-29) sequence | 5 mg and 10 mg |
| Tesamorelin | C221H366N72O67S | trans-3-hexenoyl-modified GHRH-based sequence as listed | 10 mg |
The ghrelin-receptor ligands are small pentapeptides and hexapeptides that contain unnatural residues; the GHRH-receptor ligands are much larger. A 1:1 mass ratio therefore means a very different molar ratio, which is why a stack must be reported in moles, not only in milligrams. Convert with moles = mass ÷ molecular weight for each component before comparing designs or reading someone else's.
A worked plate layout for a two-receptor study
A minimal in vitro design for a pituitary cell model has five groups run in parallel on the same plate, with at least three independent biological replicates:
- Vehicle control (same diluent and final solvent percentage as all other wells).
- GHRH-receptor ligand alone, across a log-spaced concentration series.
- Ghrelin-receptor ligand alone, across the same series.
- The two together in a fixed molar ratio across the same series.
- Combination plus a receptor-selective antagonist, to show which receptor carries the signal.
Analysis then compares group 4 with the reference predicted from groups 2 and 3. The choice of reference (Loewe additivity or Bliss independence) is made before the experiment, not after seeing the data. A study that skips groups 2 and 3 and reports only the mixture cannot claim synergy.
Pitfalls that undermine stack experiments
- Reporting by mass only. Different molecular weights make mass ratios misleading.
- Different diluents per arm. The vehicle must be identical across all groups.
- Assuming stability in the mix. Two peptides in one solution can behave differently from each alone; check by HPLC.
- Ignoring receptor desensitization. Continuous exposure of a receptor can blunt its response in culture, so the exposure schedule is part of the design, and perifusion systems mimic pulsatile exposure better than static wells.
- Over-reading a single cell model. Pituitary-derived lines and primary cultures differ in receptor expression, so confirm which receptors the system expresses before interpreting a result.
How these stacks differ from incretin-family compounds
Growth-hormone-axis stacks and incretin-family compounds are sometimes lumped together as "metabolic" research, but they act on different receptor families and answer different questions. The GHRH and ghrelin receptors control release of a pituitary hormone, while an agent such as retatrutide engages the GIP, GLP-1 and glucagon receptors, which is the subject of the retatrutide research overview. The experimental systems also differ: pituitary cell and perifusion models for the first group, receptor-expressing cell lines and metabolic readouts for the second. A design that mixes the two families in one well needs its own justification and its own controls, since the pathways are not expected to overlap at the receptor level.
Pre-mixed blend or separate vials?
| Factor | Pre-mixed blend | Separate vials |
|---|---|---|
| Ratio | Fixed by the supplier | Chosen by the investigator |
| Single-agent controls | Need separate single-compound vials anyway | Already on hand |
| Handling steps | One reconstitution | Two reconstitutions and a mixing step |
| Ratio-response studies | Not possible without extra vials | Straightforward |
| Mixing error | Eliminated at the manufacturing step | Depends on lab technique |
The comparison is expanded in CJC-1295 and ipamorelin: blend versus separate vials. A blend suits experiments where a fixed 1:1 or other defined ratio is the design; separate vials suit ratio-response work. Either way, add the single-compound controls.
Choosing an individual compound
If the design needs only one receptor, the individual comparisons help: ipamorelin versus GHRP-2, hexarelin versus ipamorelin, sermorelin versus ipamorelin and tesamorelin versus sermorelin. The wider context against the full hormone is in growth-hormone secretagogues versus HGH.
Reading "synergy" claims critically
The word synergy is used loosely in the stack literature and in product copy. In pharmacology it has a defined meaning: a combined effect greater than the reference expected from the single agents under a stated model. Three questions expose weak claims. Which reference model was used, and was it chosen in advance? Were both single-agent concentration series run in the same experiment as the combination? And does the effect size exceed the variability between independent replicates? A statement that two compounds "work better together" without those three answers is a description of a mixture, not evidence of cooperation. Where a source reports only a combined result, regard it as a hypothesis to be tested with your own single-agent and combination arms, and cite it as what it is: a single report in one system, preferably confirmed by a second laboratory.
The same caution applies to the relationship between cell-culture and organism-level results. Pituitary cells in a dish lack the hypothalamic, feedback and peripheral context that shapes the axis in a living animal, so a bench result describes receptor behavior in that system and nothing wider.
Handling and documentation
Each product page lists a lyophilized powder with refrigeration at 2–8 °C, −20 °C for long-term storage and protection from heat, moisture and light. Dissolve one compound at a time, check that it is clear, and only then combine; keep a record of lot numbers, diluent, order of addition and storage. Compound lot documents, where published, are in the COA library; CJC-1295 and ipamorelin purity testing explains how to read them. For concentration planning use the calculator, and for the wider range of compounds see the catalog.
Frequently asked questions
What is a GH secretagogue stack?
A combination of two compounds that act on the growth-hormone axis through different receptors, typically a GHRH-receptor ligand plus a ghrelin-receptor (GHS-R1a) ligand.
Which V8 blends combine these receptor routes?
CJC-1295 (no DAC) with ipamorelin, and tesamorelin with ipamorelin. Each is a two-component lyophilized product; sizes are listed on the product pages.
Why is there no single top-ranked stack?
Suitability depends on the research question. A fixed-ratio blend suits some designs, separate vials suit ratio-response work, and single-receptor questions need only one compound.
What does CJC-1295 no DAC mean?
It is the unconjugated GRF analogue form, as opposed to the version with a drug affinity complex that extends its half-life. The two are compared in a separate article.
Why are single-agent controls still needed with a blend?
A combination result is only interpretable relative to what each component does alone. Without single-agent arms, synergy or antagonism cannot be assessed.
Can the two peptides be mixed in one vial?
Pre-mixed blends are supplied that way. If mixing your own, dissolve each separately, confirm clarity, then combine and check stability by HPLC over the intended storage time.
How is concentration worked out for a two-component vial?
For each component, concentration equals its mass divided by the diluent volume. The calculator on the site performs the conversion.
How should these products be stored?
The product pages list refrigeration at 2–8 °C, −20 °C for long-term storage and protection from heat, moisture and light.
Do these articles describe effects in people?
No. They describe receptor biology and experimental design for laboratory research use only.
Related reading: Longevity Research Peptide Stacks: A 2026 Design Guide, Research Peptide Stacks: How to Read a Blend Label, Research Peptide Supplier Checklist: 10 Things to Verify.
References
- Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006;58(3):621-681. doi:10.1124/pr.58.3.10
- Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3(3):e00149. doi:10.1002/prp2.149
- Vergote V, Burvenich C, Van de Wiele C, De Spiegeleer B. Quality specifications for peptide drugs: a regulatory-pharmaceutical approach. J Pept Sci. 2009;15(11):697-710. doi:10.1002/psc.1167
